TTRX
Turn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.80
−2.68%Aug 20, 2026, 13:00 UTC
Turn Therapeutics announced new peer-reviewed research showing its product GX-03 selectively reduces key drivers of skin inflammation and itch.
Source:Aug 18, 2026, 00:00 UTC
Turn Therapeutics Inc. completed the full cashless exercise of a warrant to purchase its common stock, issuing 579,664 shares of common stock to GEM Global Yield LLC SCS and GEM Yield Bahamas Limited at an exercise price of $5.03 per share, relying on the Section 4(a)(2) exemption for accredited investors.
Aug 12, 2026, 20:30 UTC
Turn Therapeutics Inc. reported financial results for the three and six months ended June 30, 2026.
Source:Jul 7, 2026, 18:20 UTC
Turn Therapeutics announced refinements to the Phase 2 trial design of GX-03 for atopic dermatitis and an expansion of the patient population.
Source: